Meredith McKean, MD, MPH, discusses the rationale for investigating the LAG-3 inhibitor fianlimab in combination with cemiplimab-rwlc in patients with advanced melanoma, highlighting the combination's efficacy in both PD-1 inhibitor-exposed and –naïve populations, as well as the combinations its potential clinical significance within the advanced melanoma space.
University of Pittsburgh researcher, Dr. Lawrence Andrews, shares his latest work unraveling the synergistic role of PD-1 and LAG-3 in cancer immune evasion
Immutep Secures United States Patent For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
December 29, 2020 16:54 ET | Source: Immutep Limited Immutep Limited Sydney, AUSTRALIA
Sydney, AUSTRALIA, Dec. 30, 2020 (GLOBE NEWSWIRE) Immutep Limited (ASX: IMM; NASDAQ: IMMP) ( Immutep“ or “the Company“), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled “Combined Preparations for the Treatment of Cancer or Infection” by the United States Patent & Trade Mark Office.
This United States patent follows the grant of the corresponding European patent announced in November 2018. The claims of the patent protect Immutep’s intellectual property relating to combined preparations comprising its lead active immunotherapy candidate eftilagimod alpha (“efti” or “IMP321”) and a PD-1 pathway inh